<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876874</url>
  </required_header>
  <id_info>
    <org_study_id>RA and lymphatic vessels</org_study_id>
    <nct_id>NCT02876874</nct_id>
  </id_info>
  <brief_title>Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage</brief_title>
  <official_title>the Relationship Between the Activity of Rheumatoid Arthritis（RA） and Popliteal/Epitrochlear Lymph Node Morphology and the Drainage of Hand/Foot Superficial Lymphatic Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the relationship between the activity of rheumatoid arthritis and&#xD;
      popliteal/epitrochlear lymph node morphology and the drainage of hand/foot superficial&#xD;
      lymphatic vessels&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid Arthritis patients and health participants will be recruited in our research. Then&#xD;
      the classification of American College of Rheumatology/European League Against Rheumatism&#xD;
      (ACR/EULAR) 2009 will be used to identify rheumatoid arthritis patients. The measurement of&#xD;
      disease activity are Disease Activity Score 28 (DAS28) combined with the synovitis, bone&#xD;
      edema and bone erosion of hand and wrist detected by magnetic resonance (MR) and Doppler&#xD;
      ultrasound (DUS).The morphology of lymph node in popliteal/epitrochlear are scanned by&#xD;
      3-dimensional MR and DUS. The drainage of hand/foot superficial lymphatic vessels are&#xD;
      detected in sight of near infrared ray (NIR) with the applying of Indocyanine Green (ICG)&#xD;
      subcutaneously. We'll conduct correlation analysis to reveal the relationship between the&#xD;
      activity of Rheumatoid Arthritis and lymph nodes morphology and lymphatic vessels drainage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>T-initial</measure>
    <time_frame>after the injection of ICG from the first day to the fourth day after</time_frame>
    <description>the time that it takes for the ICG to be detected in vessels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>S-max</measure>
    <time_frame>after the injection of ICG, 1day after, 2 days after, 3 days after and 4days after</time_frame>
    <description>the maximum ICG signal intensity observed in the target lymph node during the first day imaging session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-max</measure>
    <time_frame>after the injection of ICG, 1day after, 2 days after, 3 days after and 4days after</time_frame>
    <description>the time it takes for a nodes in cubital fossa or popliteal space to achieve maximal ICG signal intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Clearance</measure>
    <time_frame>after the injection of ICG, 1day after, 2 days after, 3 days after and 4days after</time_frame>
    <description>an assessment of ICG wash out through the lymphatics and is quantified as the percent difference of ICG signal intensity between the two ICG-NIR images from a certain region at a) S-max (first day) and b) 24 hours post ICG injection,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>after the injection of ICG, 1day after, 2 days after, 3 days after and 4days after</time_frame>
    <description>ICG pulses that pass the a certain region within 400 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node size</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node shape</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node transverse/longitudinal diameter ratio</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node types of edges</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node thickness of cortex/medulla</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node homogeneity</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node hilum</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphatic node blood flow signal</measure>
    <time_frame>the second day after enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Lymph Node Mass</condition>
  <condition>Lymphatic Vessel; Dilatation</condition>
  <arm_group>
    <arm_group_label>the patients group</arm_group_label>
    <description>0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the health group</arm_group_label>
    <description>0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green(ICG)</intervention_name>
    <description>ICG will be injected into the dorsal of hand/foot</description>
    <arm_group_label>the health group</arm_group_label>
    <arm_group_label>the patients group</arm_group_label>
    <other_name>IC-GREEN®(indocyanine green for injection,USP),AKORN,Inc</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood 10ml for the analysis of cytokines,such as IL-1/6, TNF-α,VEGF-3&#xD;
      recepter,VEGFRC/E, et al.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study conducted in Shanghai, China. The participants will be recruited by advertisement&#xD;
        in in Longhua hospital, communities and universities in Shanghai.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients fulfilling the classification criteria of American College of&#xD;
             Rheumatology/European League Against Rheumatism (ACR/EULAR) 2009 (scores more than 6&#xD;
             points)&#xD;
&#xD;
          2. Health participants normal in the test of blood/urine/stool routine, liver and kidney&#xD;
             functions, electrocardiogram and without obvious medical history&#xD;
&#xD;
          3. Age 18 to 65 years&#xD;
&#xD;
          4. Fulling understood the whole trial and written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be excluded when they combined with:&#xD;
&#xD;
          1. other types of autoimmune diseases such as ankylosing spondylitis, systemic lupus&#xD;
             erythematosus, scleroderma, etc.,&#xD;
&#xD;
          2. lymphatic system disorders, such as lymphoma, lymphangitis and lymphatic edema due to&#xD;
             lymphatic flow disorders,&#xD;
&#xD;
          3. disorders that effect the circulation of lymph or blood vessels such as hemangiomas,&#xD;
&#xD;
          4. tumors or cancer,&#xD;
&#xD;
          5. operation history within a year, such as joint orthopedics, tumor resection, etc.,&#xD;
&#xD;
          6. allergies or allergic to iodine, or radioactive iodine treatment within the last year,&#xD;
&#xD;
          7. with metal objects inside, such as pacemakers or nails,&#xD;
&#xD;
          8. the skin for the ultrasound inspection not intact such as eczema,ulceration, etc.,&#xD;
&#xD;
          9. lactation or pregnancy women or preparation to be pregnant within the next half year,&#xD;
&#xD;
         10. without whole limbs to inspect,&#xD;
&#xD;
         11. mania, depression or other mental disorder&#xD;
&#xD;
         12. medical disorders such as diabetes, hypertension or hyperlipidemia, etc.,&#xD;
&#xD;
         13. a history of infectious diseases such as tuberculosis, hepatitis B or HIV, etc.,&#xD;
&#xD;
         14. a history of drug abuse such as opioid analgesics, sedative-hypnotics or alcohol&#xD;
             abuse, etc.,&#xD;
&#xD;
         15. severe liver or kidney dysfunction (Alanine Aminotransferase(ALT) or Aspartate&#xD;
             Aminotransferase(AST) two times higher than the upper limit of normal, serum&#xD;
             creatinine levels more than two times the upper limit of normal);&#xD;
&#xD;
         16. poor compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-jun Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianqian Liang, Dr.</last_name>
    <phone>86-021-64875390</phone>
    <email>liangqianqiantcm@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiong Wang</last_name>
    <phone>86-13671779096</phone>
    <email>13671779096@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital, Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianqian Liang, Doctor</last_name>
      <phone>86-021-64875390</phone>
      <email>liangqianqiantcm@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiong Wang</last_name>
      <phone>86-13671779096</phone>
      <email>13671779096@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yongjun Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital, Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianqian Liang, Doctor</last_name>
      <phone>86-021-64875390</phone>
      <email>liangqianqiantcm@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiong Wang</last_name>
      <phone>86-13671779096</phone>
      <email>13671779096@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yongjun Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>lymph nodes morphology</keyword>
  <keyword>drainage of lymphatic vessels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

